MMF vs. AZA for Kidney Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2016

Study Completion Date

November 29, 2017

Conditions
Kidney Transplant
Interventions
DRUG

mycophenolate mofetil

Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.

DRUG

azathioprine

Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.

Trial Locations (6)

Unknown

"Hospital Azienda Ospedaliera Ospedali Riuniti di Bergamo Unit of Neprology and Dialysis", Bergamo

"Hospital Spedali Civili - Unit of Nephrology and Dialysis", Brescia

"Hospital Niguarda Cà Granda", Milan

"Hospital Azienda Ospedaliera di Padova -", Padua

Policlinico Gemelli, Roma

"Hospital Az. Ospedaliero-Univeristaria S. Maria della Misericordia", Udine

All Listed Sponsors
collaborator

Agenzia Italiana del Farmaco

OTHER_GOV

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00494741 - MMF vs. AZA for Kidney Transplantation | Biotech Hunter | Biotech Hunter